一项 Zipalertinib 在患有表皮生长因子受体 (EGFR) 外显子 20 插入或其他不常见突变的晚期非小细胞肺癌患者中的研究。 (REZILIENT2)
一项开放标签、2b 期、全球多中心队列试验,旨在评估 Zipalertinib 对于具有外显子 20 插入和不常见/单一或复合表皮生长因子受体突变的局部晚期或转移性非小细胞肺癌患者的安全性和有效性。
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
研究概览
地位
详细说明
This study will evaluate the safety and efficacy of zipalertinib in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations or other uncommon/single or compound Epidermal Growth Factor Receptor Proteins Mutations (EGFRmts). The drug-drug interaction (DDI) substudy will assess the potential DDI effects of zipalertinib on the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates and transporter substrates and also evaluate the relationship between zipalertinib concentration and QT interval change from baseline. Additionally, dose optimization substudy will be conducted to confirm an optimized dose of zipalertinib monotherapy.
Participants will be enrolled into 1 of the 4 following cohorts:
- Cohort A ("prior ex20ins treatment") will include participants harboring EGFR ex20ins who have progressed on or after initial treatment with standard platinum-based chemotherapy and prior treatment with an ex20ins agent for their advanced disease (administered together or separately).
- Cohort B ("first-line") will include participants harboring EGFR ex20ins who have not received prior treatment for advanced or metastatic disease and are not appropriate candidates for first-line doublet platinum-based chemotherapy or have refused first-line doublet platinum-based chemotherapy.
- Cohort C ("active brain mets") will include participants harboring EGFR ex20ins or other uncommon single or compound EGFRmts and active brain metastases and/or leptomeningeal disease (LMD). Participants may or may not have had prior treatment for advanced disease.
- Cohort D ("other uncommon EGFRmts") will include participants harboring other non-ex20ins, excluding C797S (uncommon single or compound) EGFRmts who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.
For DDI substudy, participants will be enrolled in two groups:
- CYP Cocktail Group will receive a single dose of cocktail of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
- Transporter Cocktail Group will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.
For dose-optimization substudy, participants with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor protein ex20ins mutations (EGFRmts) will be randomized to receive zipalertinib at different doses with continuous daily dosing until any discontinuation criterion is met. Participants will be enrolled into two groups: Arm A and Arm B, in which they will receive different doses of zipalertinib.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Taiho Oncology, INC
- 电话号码:+1 844-878-2446
- 邮箱:medicalinformation@taihooncology.com
学习地点
-
-
-
Brampton、加拿大、L6R 3J7
- 招聘中
- William Osler Health System - Brampton Civic Hospital
-
-
-
-
-
Adana、土耳其(türkiye)、01140
- 招聘中
- Medical Park Seyhan Hastanesi
-
Edirne、土耳其(türkiye)、22030
- 招聘中
- Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi
-
Istanbul、土耳其(türkiye)、34722
- 招聘中
- Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Istanbul、土耳其(türkiye)、34214
- 撤销
- Bagcilar Medipol Mega Universite Hastanesi
-
-
Istanbul
-
Esenyurt、Istanbul、土耳其(türkiye)、34517
- 招聘中
- Istinye Üniversite Hastanesi Liv Hospital Bahcesehir
-
-
-
-
-
Dresden、德国、01307
- 招聘中
- Uniklinik Dresden
-
Giessen、德国、35392
- 招聘中
- UKGM Studienzentrale
-
Regensburg、德国、93053
- 撤销
- UKR Innere Med II Pneumologie
-
-
Hassen
-
Kassel、Hassen、德国、34125
- 招聘中
- Gesundheit Nordhessen Holding AG
-
-
-
-
-
Cremona、意大利、26100
- 招聘中
- Azienda Socio-Sanitaria Territoriale di Cremona
-
Milan、意大利、20132
- 招聘中
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
-
Parma、意大利、43126
- 招聘中
- Azienda Ospedaliero-Universitaria di Parma
-
Ravenna、意大利、48121
- 招聘中
- Ospedale S. Maria delle Croci
-
-
Florence
-
Florence、Florence、意大利、50134
- 招聘中
- Azienda Ospedaliero - Universitaria Careggi
-
-
Forli-Cesena
-
Meldola、Forli-Cesena、意大利、47014
- 招聘中
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
-
-
-
-
-
Okayama、日本、700-8558
- 招聘中
- Okayama University Hospital
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- 招聘中
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- 招聘中
- National Cancer Center Hospital East
-
-
Hukuoka
-
Fukuoka、Hukuoka、日本、811-1395
- 招聘中
- NHO Kyushu Cancer Center
-
-
Miyagi
-
Sendai、Miyagi、日本、980-0873
- 招聘中
- Sendai Kousei Hospital
-
-
Niigata
-
Niigata、Niigata、日本、951-8566
- 招聘中
- Niigata Cancer Center Hospital
-
-
Osaka
-
Sayama、Osaka、日本、589-8511
- 招聘中
- Kindai University Hospital
-
-
Shizuoka
-
Sunto-gun、Shizuoka、日本、411-8777
- 招聘中
- Shizuoka Cancer Center
-
-
Tokyo
-
Chuo Ku、Tokyo、日本、104-0045
- 招聘中
- National Cancer Center Hospital
-
Koto-ku、Tokyo、日本、135-8550
- 招聘中
- Cancer Institute Hospital of JFCR
-
-
-
-
-
Saint-Herblain、法国、44800
- 招聘中
- Hopital Nord Laennec
-
-
Aslace
-
Strasbourg、Aslace、法国、67091
- 撤销
- Nouvel Hôpital Civil
-
-
Auvergne-Rhône-Alpes
-
Lyon、Auvergne-Rhône-Alpes、法国、69008
- 招聘中
- Centre Leon Berard
-
-
Basse-Normandie
-
Caen、Basse-Normandie、法国、14033
- 招聘中
- CHU Caen Normandie
-
-
Limousin
-
Limoges、Limousin、法国、87042
- 招聘中
- Centre Hospitalier Universitaire Limoges
-
-
New Aquitaine
-
Pessac、New Aquitaine、法国、33604
- 招聘中
- Hopital Haut Leveque
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille、Provence-Alpes-Côte d'Azur Region、法国、13015
- 招聘中
- Hôpital Nord de Marseille
-
-
Île-de-France Region
-
Boulogne-Billancourt、Île-de-France Region、法国、92100
- 招聘中
- Hopital Ambroise Pare
-
Paris、Île-de-France Region、法国、75005
- 招聘中
- Institut Curie
-
-
-
-
New South Wales
-
Bankstown、New South Wales、澳大利亚、2200
- 招聘中
- Bankstown-Lidcombe Hospital
-
Saint Leonards、New South Wales、澳大利亚、2065
- 招聘中
- Genesis Care North Shore
-
-
Western Australia
-
Joondalup、Western Australia、澳大利亚、6027
- 撤销
- Joondalup Hospital Pharmacy
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 撤销
- University of Alabama at Birmingham
-
-
California
-
Duarte、California、美国、91010
- 招聘中
- City of Hope - Duarte
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Beth Israel Deaconess Medical Center
-
-
Nevada
-
Las Vegas、Nevada、美国、89169
- 招聘中
- Comprehensive Cancer Centers of Nevada - Central Valley - Twain
-
-
New Jersey
-
Basking Ridge、New Jersey、美国、07920
- 招聘中
- Memorial Sloan Kettering Cancer Center - Basking Ridge
-
Middletown、New Jersey、美国、07748
- 招聘中
- Memorial Sloan Kettering Cancer Center - Monmouth
-
Montvale、New Jersey、美国、07645
- 招聘中
- Memorial Sloan Kettering Cancer Center - Bergen
-
-
New York
-
Commack、New York、美国、11725
- 招聘中
- Memorial Sloan Kettering Cancer Center - Commack
-
Harrison、New York、美国、10604
- 招聘中
- Memorial Sloan Kettering Cancer Center - Westchester
-
Long Island City、New York、美国、11101
- 招聘中
- MSK Cancer Center
-
Uniondale、New York、美国、11553
- 招聘中
- Memorial Sloan Kettering Cancer Center - Nassau
-
-
Ohio
-
Canton、Ohio、美国、44718
- 招聘中
- Gabrail Cancer and Research Center
-
Columbus、Ohio、美国、43219
- 撤销
- Zangmeister Cancer Center
-
Toledo、Ohio、美国、43623
- 撤销
- The Toledo Clinic Cancer Center
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 撤销
- SCRI Oncology Partners
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 招聘中
- IDS Pharmacy
-
-
-
-
England
-
Barnet、England、英国、EN5 3DJ
- 招聘中
- The Royal Free Hospital NHS Foundation Trust
-
London、England、英国、NW3 2QG
- 招聘中
- Royal Free London NHS Foundation Trust
-
Manchester、England、英国、M20 4BX
- 招聘中
- The Christie NHS Foundation Trust
-
Nottingham、England、英国、NG5 1PB
- 招聘中
- Nottingham University Hospitals NHS Trust
-
-
-
-
-
Barcelona、西班牙、08036
- 招聘中
- Hospital Clinic de Barcelona
-
Barcelona、西班牙、08017
- 招聘中
- UOMi Clinica Mi Tres Torres
-
Barcelona、西班牙、08023
- 招聘中
- Hospital Quirónsalud Barcelona
-
Jaén、西班牙、23007
- 招聘中
- Complejo Hospitalario de Jaen
-
Madrid、西班牙、28041
- 招聘中
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙、28040
- 招聘中
- Hospital Universitario Fundación Jiménez Díaz
-
Madrid、西班牙、28046
- 招聘中
- Hospital La Paz
-
Madrid、西班牙、28033
- 招聘中
- MD Anderson Cancer Center Madrid
-
-
Malaga
-
Málaga、Malaga、西班牙、29010
- 招聘中
- Hospital Regional Universitario de Málaga - Hospital General
-
-
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韩国、10408
- 撤销
- National Cancer Center - Korea
-
Suwon、Gyeonggi-do、韩国、16499
- 招聘中
- Ajou University Hospital
-
Suwon、Gyeonggi-do、韩国、16247
- 招聘中
- Saint Vincent's Hospital
-
-
Gyeongsangnamdo [Kyongsangnam-do]
-
Jinju、Gyeongsangnamdo [Kyongsangnam-do]、韩国、52727
- 招聘中
- Gyeongsang National University Hospital
-
-
Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]
-
Incheon、Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]、韩国、22332
- 招聘中
- Inha University Hospital
-
-
Jeollanam-do
-
Hwasun-gun、Jeollanam-do、韩国、58128
- 撤销
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
-
Seoul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韩国、05505
- 招聘中
- Asan Medical Center
-
Seoul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韩国、08308
- 招聘中
- Korea University Guro Hospital
-
Seoul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韩国、03080
- 招聘中
- Seoul National University Hospital
-
Soeul、Seoul Teugbyeolsi [Seoul-T'ukpyolshi]、韩国、06591
- 撤销
- Seoul St. Mary's Hospital
-
-
-
-
Hong Kong Island
-
Pok Fu Lam、Hong Kong Island、香港
- 招聘中
- Queen Mary Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Written informed consent.
-
≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.
-
Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:
Cohort A participants:
-
Documented EGFR ex20ins status, as determined by local testing performed at a Clinical Laboratory Improvement Amendments (CLIA) certified (United States [US]) or locally certified laboratory (outside the US).
-
Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.
i. Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008), and BLU451. Other prior ex20ins--directed treatment may be discussed with the Sponsor for eligibility assessment.
-
Participants with brain metastasis must be neurologically stable. Participants must have received central nervous system (CNS)-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening Period. Additionally, they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with a history of uncontrolled seizures or LMD are not eligible.
Cohort B participants:
- Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
- Participants who have not received prior treatment for advanced or metastatic disease and who are not appropriate candidates for first-line doublet platinum-based chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment.
- Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
Cohort C participants:
-
Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
-
Presence of brain metastasis(es) characterized as at least one of the following:
- Newly diagnosed and/or progressive brain metastasis(es) measurable by Response Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected to CNS-directed therapy, AND/OR
- LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.
-
Participants may not require other immediate CNS-directed therapy or will likely require other CNS directed anti-tumor therapy during the first cycle of study treatment, as judged by the Investigator.
Cohort D participants:
- Documented other uncommon single or compound EGFR non-ex20ins status (excluding C797S), as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate document.
- Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
- Participants who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.
- Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed >6 months prior to the first dose of study treatment. Participants may not have received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor (TKI).
-
-
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
-
Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Participants with insufficient tissue may be eligible following discussion with the Sponsor.
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.
-
Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.
-
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female participants are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
-
Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 1 month after the last dose of study treatment.
DDI Substudy:
-
Participant has pathologically confirmed, locally advanced or metastatic NSCLC:
a. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendments (CLIA) certified (US) or locally certified laboratory (outside of the US) local laboratory, defined as either one of the following EGFRmts:
- ex20ins EGFRmt OR
- other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) OR
- common EGFRmt (eg, ex19del or L858R)
-
Participant has progressed on or after receiving prior standard of care (SoC) systemic therapy for their locally advanced or metastatic NSCLC disease unless:
- Participant for whom no approved therapy with demonstrated clinical benefit is indicated or available,
- Participant is intolerant to the available first-line (1L) SoC treatment options, OR
- Participant has refused 1L SoC treatment options (after being appropriately informed of the treatment options, risks, and benefits).
-
Participants with brain metastasis are eligible if they fulfill all of the criteria below:
- Have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by brain imaging (MRI or CT scan) during the Screening Period,
- Are on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment,
- Are neurologically stable with no history of uncontrolled seizures.
-
ECOG PS of 0 or 1.
Dose Optimization Substudy:
-
Has pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:
- Documented EGFR ex20ins status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US)
- Progressed on or after systemic therapy standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.
Note: Progression on or after systemic therapy with amivantamab is permitted (eg, given as monotherapy or in combination with chemotherapy).
-
Participants with CNS metastases are eligible if both of the following criteria are met:
i. Measurable lesions according to RANO-BM defined as a contrast-enhancing lesion that can be accurately measured in at least one dimension, with a minimum size of 10 millimeters (mm), or at least 5 mm if MRI slice thickness is ≤ 1.5 mm ii. Previously received definitive local treatment and have stable CNS disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) OR Asymptomatic CNS metastases ≤ 2 cm in size if, in the opinion of the investigator, immediate definitive treatment is not indicated.
-
Measurable disease per RECIST 1.1.
-
Has archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers
-
ECOG PS of 0 or 1.
-
Has adequate organ function.
Exclusion Criteria:
-
Participant is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.
-
Has received any of the following within the specific time frame specified:
- Participant has received Zipalertinib (TAS6417/CLN081) at any time
- CNS radiotherapy (gamma knife radiotherapy is allowed) ≤ 12 weeks, thoracic radiotherapy ≤ 28 days, or other palliative radiation ≤ 14 days prior to the first dose of study
- Anticancer immunotherapy ≤28 days prior to the first dose of study treatment
- Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.
- Any prior treatment with an EGFR exon20ins- targeted TKI
- Participants with leptomeningeal CNS disease.
-
Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Participants with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.
-
Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.
-
Impaired cardiac function or clinically significant cardiac disease including any of the following:
- History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification.
- Serious cardiac arrhythmias requiring treatment.
- Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
-
Is unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
-
History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:
- Adequately treated basal or squamous cell carcinoma of the skin
- Cancer in situ of the breast or cervix
- Participants with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease
- Participants with concurrent malignancy clinically stable and not requiring tumor-directed treatment
-
Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.
-
History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.
-
Active bleeding disorders.
-
Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.
-
Is pregnant, lactating, or planning to become pregnant.
-
The participant is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort A ("prior ex20ins treatment")
Cohort A ("prior ex20ins treatment") participants will receive zipalertinib orally twice a day (BID) continuously until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first. |
Oral tablets
其他名称:
|
|
实验性的:Cohort B ("first-line treatment")
Cohort B participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
Oral tablets
其他名称:
|
|
实验性的:Cohort C ("active brain mets")
Cohort C participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
Oral tablets
其他名称:
|
|
实验性的:Cohort D ("other uncommon EGFRmts").
Cohort D participants will receive zipalertinib orally, BID continuously until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
Oral tablets
其他名称:
|
|
实验性的:DDI Substudy: CYP Cocktail Group
Participants will receive a single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
Oral tablets
其他名称:
Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state. |
|
实验性的:DDI Substudy: Transporter Cocktail Group
Participants will receive a single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state. Zipalertinib will be dosed, orally BID in Cycle 1 (cycle length = 21 days), followed by continuous treatment with zipalertinib until documentation of PD or until other withdrawal criteria are met, whichever comes first. |
Oral tablets
其他名称:
Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state. |
|
实验性的:Dose Optimization Substudy: Arm A
Participants will receive zipalertinib, orally, at Arm A dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria. |
Oral tablets
其他名称:
|
|
实验性的:Dose Optimization Substudy: Arm B
Participants will receive zipalertinib, orally, at Arm B dose, BID, continuously in 21-day treatment cycles until the participant meets any of the treatment discontinuation criteria. |
Oral tablets
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
队列1-4:客观响应率(ORR)
大体时间:大约2年
|
大约2年
|
|
剂量优化亚组研究:由盲态独立中心评审(BICR)评估的客观缓解率
大体时间:最长约2年
|
最长约2年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
C 组:颅内 (i) 总体缓解率 (iORR)
大体时间:最长约 2 年
|
最长约 2 年
|
|
队列C:颅内响应的持续时间(IDCR)
大体时间:大约2年
|
大约2年
|
|
队列C:颅内响应持续时间(IDOR)
大体时间:大约2年
|
大约2年
|
|
队列1-4:根据国家癌症研究所共同术语标准5.0版(CTCAE v5.0)根据国家癌症研究所共同术语标准进行的治疗紧急不良事件(TEAE)的参与者人数(TEAE)
大体时间:大约2年
|
大约2年
|
|
队列1-4:临床实验室参数临床显着变化的参与者人数
大体时间:大约2年
|
大约2年
|
|
队列1-4:生命体征临床显着变化的参与者人数
大体时间:大约2年
|
大约2年
|
|
队列1-4:心电图(ECG)参数临床显着变化的参与者数量
大体时间:大约2年
|
大约2年
|
|
队列1-4:使用心电图(ECHO)和多名采集(MUGA)扫描评估的左心室射血分数(LVEF)变化的参与者数量
大体时间:大约2年
|
大约2年
|
|
队列1-4:疾病控制率(DCR)
大体时间:大约2年
|
大约2年
|
|
队列1-4:响应持续时间(DOR)
大体时间:大约2年
|
大约2年
|
|
队列1-4:无进展生存(PFS)
大体时间:大约2年
|
大约2年
|
|
队列1-4:总生存(OS)
大体时间:大约2年
|
大约2年
|
|
队列1-4:Zipalertinib的最小血浆浓度(CMIN)
大体时间:大约2年
|
大约2年
|
|
DDI替代:使用Fridericia的公式(QTCF)间隔在Zipalertinib施用CYP鸡尾酒组后使用Fridericia的公式(QTCF)间隔更改为QT间隔的基线。
大体时间:周期1(周期长度= 21天)
|
周期1(周期长度= 21天)
|
|
DDI蛋白:在CYP组和运输蛋白鸡尾酒组中多剂量施用Zipalertinib后,几何平均最大血浆浓度(CMAX)
大体时间:周期1(周期长度= 21天)
|
周期1(周期长度= 21天)
|
|
DDI替代:在CYP组和运输蛋白鸡尾酒组中多剂量施用Zipalertinib之后,曲线下的几何平均面积(AUC)
大体时间:周期1(周期长度= 21天)
|
周期1(周期长度= 21天)
|
|
Ddi ordudy:CYP组和运输鸡尾酒中有治疗急需不良事件(TEAE)的参与者数量
大体时间:周期1(周期长度= 21天)
|
周期1(周期长度= 21天)
|
|
剂量优化子研究:由BICR和研究者评估的缓解持续时间(DoR)
大体时间:最多约2年
|
最多约2年
|
|
剂量优化亚研究:由BICR和研究者评估的应答时间
大体时间:最长约2年
|
最长约2年
|
|
剂量优化亚研究:BICR和研究者评估的肿瘤大小相对基线的百分比变化
大体时间:最长约2年
|
最长约2年
|
|
剂量优化亚研究:由BICR和研究者评估的DCR
大体时间:最长约2年
|
最长约2年
|
|
剂量优化亚组研究:BICR与研究者评估的无进展生存期
大体时间:最长约2年
|
最长约2年
|
|
剂量优化亚研究:6个月无进展生存率
大体时间:最长约 2 年
|
最长约 2 年
|
|
剂量优化子研究:研究者评估的客观缓解率
大体时间:约2年
|
约2年
|
|
剂量优化亚组研究:总生存期 (OS)
大体时间:最长约2年
|
最长约2年
|
|
剂量优化子研究:基于神经肿瘤学脑转移反应评估(RANO-BM)标准的颅内客观缓解率(iORR)
大体时间:最多约2年
|
最多约2年
|
|
剂量优化亚研究:颅内缓解持续时间(iDOR)
大体时间:最长约2年
|
最长约2年
|
|
剂量优化子研究:颅内疾病控制率 (iDCR)
大体时间:最长约2年
|
最长约2年
|
|
剂量优化子研究:发生不良事件(AEs)和严重不良事件(SAEs)的参与者人数
大体时间:最长约2年
|
最长约2年
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- TAS6417-201
- 2023-503865-48 (EudraCT编号)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.